PMID- 21316602 OWN - NLM STAT- MEDLINE DA - 20110214 DCOM- 20110323 IS - 1878-3686 (Electronic) IS - 1535-6108 (Linking) VI - 19 IP - 2 DP - 2011 Feb 15 TI - Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. PG - 232-43 AB - The full scale of human miRNome in specific cell or tissue, especially in cancers, remains to be determined. An in-depth analysis of miRNomes in human normal liver, hepatitis liver, and hepatocellular carcinoma (HCC) was carried out in this study. We found nine miRNAs accounted for approximately 88.2% of the miRNome in human liver. The third most highly expressed miR-199a/b-3p is consistently decreased in HCC, and its decrement significantly correlates with poor survival of HCC patients. Moreover, miR-199a/b-3p can target tumor-promoting PAK4 to suppress HCC growth through inhibiting PAK4/Raf/MEK/ERK pathway both in vitro and in vivo. Our study provides miRNomes of human liver and HCC and contributes to better understanding of the important deregulated miRNAs in HCC and liver diseases. CI - Copyright (c) 2011 Elsevier Inc. All rights reserved. AD - National Key Laboratory of Medical Immunology & Institute of Immunology, Second Military Medical University, Shanghai 200433, China. FAU - Hou, Jin AU - Hou J FAU - Lin, Li AU - Lin L FAU - Zhou, Weiping AU - Zhou W FAU - Wang, Zhengxin AU - Wang Z FAU - Ding, Guoshan AU - Ding G FAU - Dong, Qiongzhu AU - Dong Q FAU - Qin, Lunxiu AU - Qin L FAU - Wu, Xiaobing AU - Wu X FAU - Zheng, Yuanyuan AU - Zheng Y FAU - Yang, Yun AU - Yang Y FAU - Tian, Wei AU - Tian W FAU - Zhang, Qian AU - Zhang Q FAU - Wang, Chunmei AU - Wang C FAU - Zhang, Qinghua AU - Zhang Q FAU - Zhuang, Shi-Mei AU - Zhuang SM FAU - Zheng, Limin AU - Zheng L FAU - Liang, Anmin AU - Liang A FAU - Tao, Wenzhao AU - Tao W FAU - Cao, Xuetao AU - Cao X LA - eng SI - GEO/GSE21279 PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Cancer Cell JT - Cancer cell JID - 101130617 RN - 0 (MicroRNAs) SB - IM MH - Carcinoma, Hepatocellular/*genetics/metabolism/therapy MH - DNA Methylation MH - Hepatitis B/genetics MH - Hepatitis C/genetics MH - Humans MH - Liver/*metabolism MH - Liver Neoplasms/*genetics/metabolism/therapy MH - MicroRNAs/*genetics MH - Reverse Transcriptase Polymerase Chain Reaction MH - Survival Analysis EDAT- 2011/02/15 06:00 MHDA- 2011/03/24 06:00 CRDT- 2011/02/15 06:00 PHST- 2010/04/01 [received] PHST- 2010/10/10 [revised] PHST- 2010/12/29 [accepted] AID - S1535-6108(11)00002-X [pii] AID - 10.1016/j.ccr.2011.01.001 [doi] PST - ppublish SO - Cancer Cell. 2011 Feb 15;19(2):232-43. PMID- 21273524 OWN - NLM STAT- MEDLINE DA - 20110128 DCOM- 20110317 IS - 1527-1315 (Electronic) IS - 0033-8419 (Linking) VI - 258 IP - 2 DP - 2011 Feb TI - Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. PG - 627-34 AB - PURPOSE: To determine the efficacy and safety of transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) and main portal vein (MPV) invasion. MATERIALS AND METHODS: This study was approved by the institutional review board, and the requirement to obtain informed consent was waived. The authors retrospectively assessed the electronic medical records of patients in whom HCC with MPV invasion was newly diagnosed from January 2004 to December 2007 at a single tertiary medical center. Patients with decompensated hepatic function were excluded. Outcomes of patients treated with TACE were compared with those of patients given supportive care according to Child-Pugh class. RESULTS: One hundred twenty-five patients (104 men and 21 women; mean age, 55.7 years; age range, 33.4-83.0 years) were included. The median overall survival was 3.7 months (range, 0.2-33.3 months). Eighty-three of the 125 patients (66.4%) were treated with TACE and 42 (33.6%) received supportive care. Repeated TACE showed significant survival benefits compared with supportive care in patients with Child-Pugh class A (median survival, 7.4 months vs 2.6 months, respectively; P < .001) and class B (median survival, 2.8 months vs 1.9 months, respectively; P = .002) disease. Results of multivariate analysis showed that treatment with TACE (hazard ratio, 0.263; 95% confidence interval [CI]: 0.164, 0.424; P < .001) and Child-Pugh class A status (hazard ratio, 0.550; 95% CI: 0.368, 0.822; P = .004) were independent predictive factors of a favorable outcome. There were no procedure-related deaths within 4 weeks after TACE, and patient morbidity was 28.9% (24 of 83 patients). CONCLUSION: TACE can be performed safely and may improve the overall survival of patients with HCC and MPV invasion. CI - (c) RSNA, 2011. AD - Department of Internal Medicine, Gangnam Healthcare Center, Seoul National University Hospital, 28 Yungun-dong, Chongno-gu, Seoul 110-744, Korea. FAU - Chung, Goh Eun AU - Chung GE FAU - Lee, Jeong-Hoon AU - Lee JH FAU - Kim, Hwi Young AU - Kim HY FAU - Hwang, Sang Youn AU - Hwang SY FAU - Kim, Joon Suk AU - Kim JS FAU - Chung, Jin Wook AU - Chung JW FAU - Yoon, Jung-Hwan AU - Yoon JH FAU - Lee, Hyo-Suk AU - Lee HS FAU - Kim, Yoon Jun AU - Kim YJ LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Radiology JT - Radiology JID - 0401260 RN - 15663-27-1 (Cisplatin) RN - 23214-92-8 (Doxorubicin) RN - 50-07-7 (Mitomycin) RN - 8008-53-5 (Ethiodized Oil) SB - AIM SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Hepatocellular/*drug therapy/mortality/radiography MH - Chemoembolization, Therapeutic/*methods MH - Cisplatin/administration & dosage MH - Doxorubicin/administration & dosage MH - Ethiodized Oil/administration & dosage MH - Female MH - Gelatin Sponge, Absorbable/administration & dosage MH - Humans MH - Liver Neoplasms/*drug therapy/mortality/radiography MH - Male MH - Middle Aged MH - Mitomycin/administration & dosage MH - *Portal Vein MH - Retrospective Studies MH - Survival Rate MH - Tomography, X-Ray Computed MH - Treatment Outcome EDAT- 2011/01/29 06:00 MHDA- 2011/03/18 06:00 CRDT- 2011/01/29 06:00 AID - 258/2/627 [pii] AID - 10.1148/radiol.10101058 [doi] PST - ppublish SO - Radiology. 2011 Feb;258(2):627-34. PMID- 21259246 OWN - NLM STAT- MEDLINE DA - 20110124 DCOM- 20110311 IS - 1096-9098 (Electronic) IS - 0022-4790 (Linking) VI - 103 IP - 2 DP - 2011 Feb TI - Delay in treatment of early-stage hepatocellular carcinoma using radiofrequency ablation may impact survival of cirrhotic patients in a surveillance program. PG - 133-9 LID - 10.1002/jso.21797 [doi] AB - BACKGROUND: The aim of this study was to evaluate the impact of the interval between diagnosis and treatment using radiofrequency (RF) ablation on the survival of patients with HCC detected through a surveillance program. METHODS: Between January 2004 and July 2007, 121 cirrhotic patients with 157 tumours detected through a surveillance program underwent RF ablation. A delay in treatment was defined as >5 weeks. The mean length of follow-up was 25 months (range 8-55 months). Cumulative survival of patients was analysed using the Kaplan-Meier method. Cox regression models were used to identify factors associated with patient survival. RESULTS: The 1-, 2- and 3-year survival rates were 92.5%, 78.5% and 67.2%. The independent predictors of poorer patient survival were time from diagnosis to treatment >5 weeks (pooled odds ratio [OR], 3.59; 95% confidence interval [CI], 1.58-8.18; P = 0.002), absence of complete ablation after the initial RF session (OR, 2.42; 95% CI 1.07-5.45; P = 0.033) and Child-Pugh B liver cirrhosis (OR, 2.46; 95% CI 1.06-5.70; P = 0.036). CONCLUSIONS: Delay in the start of effective treatment for HCC using RF ablation may be associated with poorer patient survival. CI - Copyright (c) 2010 Wiley-Liss, Inc. AD - Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan. FAU - Chen, Wei-Ting AU - Chen WT FAU - Fernandes, Mark Lee AU - Fernandes ML FAU - Lin, Chen-Chun AU - Lin CC FAU - Lin, Shi-Ming AU - Lin SM LA - eng PT - Journal Article DEP - 20101207 PL - United States TA - J Surg Oncol JT - Journal of surgical oncology JID - 0222643 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Hepatocellular/diagnosis/*epidemiology/*surgery MH - *Catheter Ablation MH - Chronic Disease MH - Comorbidity MH - Confidence Intervals MH - Delayed Diagnosis MH - Female MH - Follow-Up Studies MH - Humans MH - Liver Cirrhosis/*mortality MH - Liver Neoplasms/diagnosis/*epidemiology/*surgery MH - Male MH - Middle Aged MH - Population Surveillance MH - Prospective Studies MH - Survival Rate EDAT- 2011/01/25 06:00 MHDA- 2011/03/12 06:00 CRDT- 2011/01/25 06:00 PHST- 2010/08/17 [received] PHST- 2010/10/11 [accepted] PHST- 2010/12/07 [aheadofprint] AID - 10.1002/jso.21797 [doi] PST - ppublish SO - J Surg Oncol. 2011 Feb;103(2):133-9. doi: 10.1002/jso.21797. Epub 2010 Dec 7. PMID- 21257869 OWN - NLM STAT- MEDLINE DA - 20110124 DCOM- 20110303 IS - 1546-3141 (Electronic) IS - 0361-803X (Linking) VI - 196 IP - 2 DP - 2011 Feb TI - Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. PG - W220 FAU - Daniels, John R AU - Daniels JR LA - eng PT - Comment PT - Letter PL - United States TA - AJR Am J Roentgenol JT - AJR. American journal of roentgenology JID - 7708173 RN - 8008-53-5 (Ethiodized Oil) SB - AIM SB - IM CON - AJR Am J Roentgenol. 2010 Mar;194(3):830-7. PMID: 20173167 MH - Carcinoma, Hepatocellular/*mortality/*therapy MH - Cause of Death MH - *Chemoembolization, Therapeutic MH - Ethiodized Oil/*administration & dosage MH - Humans MH - Injections, Intra-Arterial MH - Liver Neoplasms/*mortality/*therapy MH - Proportional Hazards Models MH - Research Design MH - Survival Analysis MH - Survival Rate EDAT- 2011/01/25 06:00 MHDA- 2011/03/04 06:00 CRDT- 2011/01/25 06:00 AID - 196/2/W220 [pii] AID - 10.2214/AJR.10.4558 [doi] PST - ppublish SO - AJR Am J Roentgenol. 2011 Feb;196(2):W220. PMID- 21257838 OWN - NLM STAT- MEDLINE DA - 20110124 DCOM- 20110228 IS - 1748-880X (Electronic) IS - 0007-1285 (Linking) VI - 84 IP - 998 DP - 2011 Feb TI - Use of the triaxial microcatheter method in super-selective transcatheter arterial chemoembolisation for hepatocellular carcinoma. PG - 184-7 AB - OBJECTIVES: Transcatheter arterial chemoembolisation (TACE) has been widely used for inoperable hepatocellular carcinoma (HCC). Super-selective TACE is preferable to non-selective therapy, because it maximises the impact of treatment on the tumour while minimising damage to tumour-free liver parenchyma. It is therefore important to advance the catheter tip as close as possible in the feeding artery. There is now a new microcatheter with a 1.9-Fr tip with no taper, which can be inserted into a 2.7-Fr microcatheter. In this study we describe the new technique of using the two microcatheters called the triaxial microcatheter method. METHODS: We evaluated 30 TACE procedures to investigate whether or not the catheter tip could be advanced closer to HCC with the triaxial microcatheter method than with previous TACE using a conventional microcatheter. RESULTS: With conventional microcatheters, the level of embolisation was a lobar artery in 4 cases, segmental in 8 cases, subsegmental in 15 cases and sub-subsegmental in only 1 case. TACE could not be performed in two cases. When using the triaxial microcatheter method the level of embolisation was subsegmental in 8 cases, including 2 in which the level was the same as that with a conventional microcatheter, sub-subsegmental in 13 cases and more distal in 7 cases. In the two cases in which TACE could not be performed with the conventional microcatheter, it could be performed sufficiently using the new method. As a whole, in 28 of the 30 procedures (93%) we could successfully advance a catheter tip closer than with the previous TACE. CONCLUSION: The triaxial microcatheter method appears to be useful. AD - Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Japan. m_shimohira@yahoo.co.jp FAU - Shimohira, M AU - Shimohira M FAU - Ogino, H AU - Ogino H FAU - Kawai, T AU - Kawai T FAU - Kushita, A AU - Kushita A FAU - Watanabe, M AU - Watanabe M FAU - Kawaguchi, T AU - Kawaguchi T FAU - Kurono, K AU - Kurono K FAU - Shibamoto, Y AU - Shibamoto Y LA - eng PT - Journal Article PL - England TA - Br J Radiol JT - The British journal of radiology JID - 0373125 SB - AIM SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Hepatocellular/blood supply/*therapy MH - Catheterization MH - Chemoembolization, Therapeutic/*methods MH - Female MH - Humans MH - Liver Neoplasms/blood supply/*therapy MH - Male MH - Middle Aged MH - Treatment Outcome EDAT- 2011/01/25 06:00 MHDA- 2011/03/01 06:00 CRDT- 2011/01/25 06:00 AID - 84/998/184 [pii] AID - 10.1259/bjr/26974088 [doi] PST - ppublish SO - Br J Radiol. 2011 Feb;84(998):184-7. PMID- 21214943 OWN - NLM STAT- MEDLINE DA - 20110119 DCOM- 20110317 IS - 1477-7819 (Electronic) IS - 1477-7819 (Linking) VI - 9 DP - 2011 TI - Surgical outcome of hepatocellular carcinoma patients with biliary tumor thrombi. PG - 2 AB - BACKGROUND: To investigate the surgical outcome of hepatocellular carcinoma (HCC) patients with biliary tumor thrombi (BTT). METHODS: Surgical outcome of 27 HCC patients with BTT (group I) were compared with randomly selected HCC patients without BTT (group II; n = 270). RESULTS: One patient in group I died of hepatic failure within 30 days after resection. The 1-, 3- and 5-year cumulative survival rates of group I were 70.3%, 25.9%, and 7.4%, respectively; these were significantly lower than those of group II (90.6%, 54.0%, and 37.7%) (P <0.001). The rates of early recurrence (400 ng/mL, 20 (64.5%) had a >20% decrease after 2 cycles of treatment. The median TTP and OS were 5.8 and 22.5 months, respectively. Hematologic toxicity was the most common side effect, including neutropenia (17%) and anemia (7%). CONCLUSIONS: The combination of gemcitabine plus pegylated liposomal doxorubicin was active and safe in advanced HCC. Moreover, this treatment induced some complete responses and converted some untreatable HCCs into lesions eligible for resection or transplantation. CI - (c) 2010 American Cancer Society. AD - Department of Medical Oncology 1 Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy. lombardi.giuseppe.lg@gmail.com FAU - Lombardi, Giuseppe AU - Lombardi G FAU - Zustovich, Fable AU - Zustovich F FAU - Farinati, Fabio AU - Farinati F FAU - Cillo, Umberto AU - Cillo U FAU - Vitale, Alessandro AU - Vitale A FAU - Zanus, Giacomo AU - Zanus G FAU - Donach, Martin AU - Donach M FAU - Farina, Miriam AU - Farina M FAU - Zovato, Stefania AU - Zovato S FAU - Pastorelli, Davide AU - Pastorelli D LA - eng PT - Clinical Trial, Phase II PT - Journal Article DEP - 20100831 PL - United States TA - Cancer JT - Cancer JID - 0374236 RN - 0 (Polyethylene Glycols) RN - 0 (pegylated liposomal doxorubicin) RN - 103882-84-4 (gemcitabine) RN - 23214-92-8 (Doxorubicin) RN - 951-77-9 (Deoxycytidine) SB - AIM SB - IM MH - Adult MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use MH - Carcinoma, Hepatocellular/*drug therapy/mortality MH - Deoxycytidine/administration & dosage/*analogs & derivatives MH - Disease-Free Survival MH - Doxorubicin/administration & dosage/*analogs & derivatives MH - Female MH - Humans MH - Liver Neoplasms/*drug therapy/mortality MH - Male MH - Middle Aged MH - Polyethylene Glycols/*administration & dosage EDAT- 2010/11/09 06:00 MHDA- 2011/03/02 06:00 CRDT- 2010/11/09 06:00 PHST- 2010/05/24 [received] PHST- 2010/07/07 [revised] PHST- 2010/08/19 [accepted] PHST- 2010/08/31 [aheadofprint] AID - 10.1002/cncr.25578 [doi] PST - ppublish SO - Cancer. 2011 Jan 1;117(1):125-33. doi: 10.1002/cncr.25578. Epub 2010 Aug 31. PMID- 21047696 OWN - NLM STAT- MEDLINE DA - 20101130 DCOM- 20110324 IS - 0168-8278 (Print) IS - 0168-8278 (Linking) VI - 54 IP - 1 DP - 2011 Jan TI - Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. PG - 108-14 AB - BACKGROUND & AIMS: Patients with hepatocellular carcinoma (HCC) in a palliative setting have a poor prognosis despite recent therapeutic progress. Several prognostic scores, such as the BCLC and the CLIP, have been shown to be useful in helping select treatment options ranging from transplantation to palliative care. However, the discriminatory ability of these scores is inadequate in palliative settings, which concern about 70% of HCC patients. In this paper, we propose and validate a new prognostic score for patients in the palliative setting. METHODS: The prognostic score was developed on a set of 416 patients from a negative randomized clinical trial conducted by the Federation Francophone de Cancers Digestifs. It was then subsequently validated on a second set of 271 patients from another negative trial. Backward selection was used to identify independent baseline characteristics. Measures of discrimination and predictive values were computed to assess the quality of the developed score. Comparisons with the BCLC and the CLIP - with and without the WHO performance status (PS) score - were performed. RESULTS: Tumour morphology, portal vein obstruction, metastasis, ascites, jaundice, alpha-foetoprotein, and serum alkaline phosphatase were included in the final score. From the training dataset, three groups of increasing risk were defined, and these were associated with hazard ratios (HR) of 2.13 and HR = 5.72. Similar results were obtained on the validation dataset. This score provides a better discriminatory ability than BCLC and CLIP in this setting. Unfortunately, absolute performances for these scores remain poor. CONCLUSIONS: The new prognostic score and CLIP + PS are recommended in palliative settings. However, new prognostic variables are necessary. CI - Copyright (c) 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. AD - Unite d'Epidemiologie et Biostatistique, Inserm CIC P802, CHU Poitiers, Universite de Poitiers, France. caroline.tournoux-facon@chu-poitiers.fr FAU - Tournoux-Facon, Caroline AU - Tournoux-Facon C FAU - Paoletti, Xavier AU - Paoletti X FAU - Barbare, Jean-Claude AU - Barbare JC FAU - Bouche, Olivier AU - Bouche O FAU - Rougier, Philippe AU - Rougier P FAU - Dahan, Laetitia AU - Dahan L FAU - Lombard-Bohas, Catherine AU - Lombard-Bohas C FAU - Faroux, Roger AU - Faroux R FAU - Raoul, Jean Luc AU - Raoul JL FAU - Bedenne, Laurent AU - Bedenne L FAU - Bonnetain, Franck AU - Bonnetain F LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Validation Studies DEP - 20100820 PL - England TA - J Hepatol JT - Journal of hepatology JID - 8503886 RN - 0 (alpha-Fetoproteins) RN - EC 3.1.3.1 (Alkaline Phosphatase) SB - IM MH - Aged MH - Alkaline Phosphatase/blood MH - Carcinoma, Hepatocellular/*mortality/pathology/*therapy MH - Female MH - France/epidemiology MH - Humans MH - Kaplan-Meier Estimate MH - Liver Neoplasms/*mortality/pathology/*therapy MH - Male MH - Middle Aged MH - Neoplasm Staging MH - *Palliative Care MH - Predictive Value of Tests MH - Prognosis MH - Proportional Hazards Models MH - alpha-Fetoproteins/metabolism EDAT- 2010/11/05 06:00 MHDA- 2011/03/25 06:00 CRDT- 2010/11/05 06:00 PHST- 2009/09/21 [received] PHST- 2010/06/02 [revised] PHST- 2010/06/18 [accepted] PHST- 2010/08/20 [aheadofprint] AID - S0168-8278(10)00705-1 [pii] AID - 10.1016/j.jhep.2010.06.015 [doi] PST - ppublish SO - J Hepatol. 2011 Jan;54(1):108-14. Epub 2010 Aug 20. PMID- 21046672 OWN - NLM STAT- MEDLINE DA - 20101130 DCOM- 20110322 IS - 1932-8494 (Electronic) IS - 1932-8486 (Linking) VI - 293 IP - 12 DP - 2010 Dec TI - Involvement of genetic instability in the downregulation of sFRP1 in Chinese patients with hepatocellular carcinoma. PG - 2020-6 AB - Secreted frizzled-related protein 1 (sFRP1) is a new tumor suppressor based on recent researches, but the correlation of the genetic instability of sFRP1 gene with the clinicopathologic features of the hepatocellular carcinoma (HCC) has not been studied in Chinese people. In this study, 42 pairs of paraffin-embedded HCC and adjacent non-carcinoma tissues were examined for the loss of heterozygosity (LOH) and microsatellite instability (MSI) of two microsatellite markers D8S532 and D8S1722 located in the vicinity of the sFRP1 gene. Envision immunohistochemistry was used to assess the expression of sFRP1. We found that the reduced expression of the sFRP1 protein was frequently observed in Chinese patients with HCC, which may at least partially result from the genetic instability, especially LOH. The LOH-associated sFRP1 downregulation may play an important role in the development of HCC. AD - State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. FAU - Qiu, Yunqing AU - Qiu Y FAU - Xu, Liqian AU - Xu L FAU - Zhou, Yang-Huai AU - Zhou YH FAU - Shi, Ming AU - Shi M FAU - Ma, Yingyu AU - Ma Y FAU - Li, Meng AU - Li M FAU - Li, Ji-Cheng AU - Li JC LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Anat Rec (Hoboken) JT - Anatomical record (Hoboken, N.J. : 2007) JID - 101292775 RN - 0 (Intercellular Signaling Peptides and Proteins) RN - 0 (Membrane Proteins) RN - 0 (SFRP1 protein, human) SB - IM MH - Adult MH - Aged MH - Asian Continental Ancestry Group/*genetics MH - Carcinoma, Hepatocellular/ethnology/*genetics MH - Down-Regulation/genetics MH - Humans MH - Intercellular Signaling Peptides and Proteins/*genetics/metabolism MH - Liver Neoplasms/ethnology/*genetics MH - Loss of Heterozygosity/genetics MH - Male MH - Membrane Proteins/*genetics/metabolism MH - Microsatellite Instability MH - Middle Aged MH - Polymorphism, Single-Stranded Conformational/genetics EDAT- 2010/11/04 06:00 MHDA- 2011/03/23 06:00 CRDT- 2010/11/04 06:00 AID - 10.1002/ar.21273 [doi] PST - ppublish SO - Anat Rec (Hoboken). 2010 Dec;293(12):2020-6. PMID- 21042835 OWN - NLM STAT- MEDLINE DA - 20101216 DCOM- 20110328 IS - 1573-4919 (Electronic) IS - 0300-8177 (Linking) VI - 347 IP - 1-2 DP - 2011 Jan TI - Functional polymorphisms of cyclooxygenase-2 gene and risk for hepatocellular carcinoma. PG - 201-8 AB - Cyclooxygenase-2 (COX-2) influences carcinogenesis through immune response suppression, apoptosis inhibition, regulation of angiogenesis and tumor cell invasion, and metastasis. It is now well established that COX-2 is overexpressed in many premalignant, malignant, and metastatic cancers, including hepatocellular carcinoma (HCC). DNA sequence variations in the COX-2 gene may lead to altered COX-2 production and/or activity, and so they cause inter-individual differences in the susceptibility to HCC. Functional coding region polymorphisms -1195A>G (rs689466), -765G>C (rs20417), and +8473T>C (rs5275) in the COX-2 gene have recently been shown to be associated with several human cancers but their association with HCC has yet to be investigated. We used hospital-based case-control study to assess the hypothesis that the functional COX-2 variation may affect individual susceptibility to the HCC. COX-2 polymorphisms were investigated in 129 confirmed subjects with HCC and 129 cancer-free control subjects matched on age, gender, smoking, and alcohol consumption using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. The distribution of the COX-2 -1195A>G and +8473T>C genotypes were not significantly different between HCC cases and control. However, proportion of the COX-2 -765CC genotype which leads to a 30% reduction of the COX-2 promoter activity was significantly lower in patients with HCC (3.1%) when compared to control subjects (11.6%) (P < 0.05). Logistic regression analyses revealed that the COX-2 -765G>C variant genotype (-765CC) was associated with a significantly decreased risk of HCC compared with the -765GG wild-type homozygotes [P < 0.05, odds ratio (OR) = 0.25, 95% confidence interval (CI) = 0.08-0.79]. Our results suggest for the first time that the -765CC genotype of COX-2 -765G>C polymorphism, causing lower COX-2 gen expression, is a genetic protective factor for HCC. However, because this is the first report concerning the COX-2 -1195A>G, -765G>C, and +8473T>C polymorphisms and the risk of HCC, independent studies are needed to validate our findings. AD - Department of Gastroenterology, Faculty of Medicine, Cukurova University, 01330, Adana, Turkey. FAU - Akkiz, Hikmet AU - Akkiz H FAU - Bayram, Suleyman AU - Bayram S FAU - Bekar, Aynur AU - Bekar A FAU - Akgollu, Ersin AU - Akgollu E FAU - Ulger, Yakup AU - Ulger Y LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20101102 PL - Netherlands TA - Mol Cell Biochem JT - Molecular and cellular biochemistry JID - 0364456 RN - EC 1.14.99.1 (Cyclooxygenase 2) RN - EC 1.14.99.1 (PTGS2 protein, human) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Hepatocellular/*enzymology/*genetics MH - Cyclooxygenase 2/*genetics MH - Female MH - Gene Frequency/genetics MH - *Genetic Predisposition to Disease MH - Humans MH - Liver Neoplasms/*enzymology/*genetics MH - Male MH - Middle Aged MH - Polymorphism, Single Nucleotide/*genetics MH - Risk Factors MH - Young Adult EDAT- 2010/11/03 06:00 MHDA- 2011/03/29 06:00 CRDT- 2010/11/03 06:00 PHST- 2010/08/10 [received] PHST- 2010/10/18 [accepted] PHST- 2010/11/02 [aheadofprint] AID - 10.1007/s11010-010-0629-9 [doi] PST - ppublish SO - Mol Cell Biochem. 2011 Jan;347(1-2):201-8. Epub 2010 Nov 2. PMID- 20970216 OWN - NLM STAT- MEDLINE DA - 20101130 DCOM- 20110324 IS - 0168-8278 (Print) IS - 0168-8278 (Linking) VI - 54 IP - 1 DP - 2011 Jan TI - Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. PG - 89-97 AB - BACKGROUND & AIMS: Microarray data showed that osteopontin overexpression predicts early HCC-recurrence after liver resection. Osteopontin (OPN) expression could serve as a predictor of HCC-recurrence after OLT. METHODS: Osteopontin expression was investigated immunohistochemically in a unique population of 125 HCC-patients undergoing OLT between 1982 and 2002, including 81 patients (65%) outside the Milan criteria. Multivariate analysis of factors associated with median overall survival (OS) and time to recurrence (TTR) was performed. RESULTS: Osteopontin was expressed in 40/125 (32%) of the HCCs. Overall survival post-OLT at 1, 2, 3, 5 years was 77%, 62%, 52%, and 43% (median survival 37 months). Overall survival was significantly longer without expression of OPN (p < 0.05; (median OS: 56 vs. 23 months). The same was true for median TTR (p = 0.008). Outside Milan criteria, patients without OPN-expression had better prognosis (median OS: 37.8 vs. 19.2 months, p = 0.003). Tumor recurrence in patients transplanted outside Milan criteria occurred in 43% (23 of 54) of patients without and 70% (19 of 27, p = 0.018) of patients with OPN-expression after a median TTR of 83.5 vs. 13.9 months. On multivariate analysis, vascular invasion and OPN-expression were independently associated with OS and TTR in HCC-patients after OLT. CONCLUSIONS: Immunohistochemically detectable Osteopontin in HCC is an independent predictor of tumor recurrence and survival in patients beyond Milan criteria undergoing OLT. CI - Copyright (c) 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. AD - Abteilung Gastroenterologie and Hepatologie, Medizinische Universitat and AKH Wien, Vienna, Austria. FAU - Sieghart, Wolfgang AU - Sieghart W FAU - Wang, Xiaowei AU - Wang X FAU - Schmid, Katharina AU - Schmid K FAU - Pinter, Matthias AU - Pinter M FAU - Konig, Franz AU - Konig F FAU - Bodingbauer, Martin AU - Bodingbauer M FAU - Wrba, Fritz AU - Wrba F FAU - Rasoul-Rockenschaub, Susanne AU - Rasoul-Rockenschaub S FAU - Peck-Radosavljevic, Markus AU - Peck-Radosavljevic M LA - eng PT - Journal Article DEP - 20100831 PL - England TA - J Hepatol JT - Journal of hepatology JID - 8503886 RN - 0 (Tumor Markers, Biological) RN - 106441-73-0 (Osteopontin) SB - IM MH - Adult MH - Aged MH - Carcinoma, Hepatocellular/*metabolism/mortality/*surgery MH - Female MH - Humans MH - Liver Neoplasms/*metabolism/mortality/*surgery MH - *Liver Transplantation MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Osteopontin/*metabolism MH - Prognosis MH - Proportional Hazards Models MH - Recurrence MH - Survival Analysis MH - Tumor Markers, Biological/metabolism EDAT- 2010/10/26 06:00 MHDA- 2011/03/25 06:00 CRDT- 2010/10/26 06:00 PHST- 2009/12/03 [received] PHST- 2010/06/16 [revised] PHST- 2010/06/18 [accepted] PHST- 2010/08/31 [aheadofprint] AID - S0168-8278(10)00722-1 [pii] AID - 10.1016/j.jhep.2010.06.030 [doi] PST - ppublish SO - J Hepatol. 2011 Jan;54(1):89-97. Epub 2010 Aug 31. PMID- 20964802 OWN - NLM STAT- MEDLINE DA - 20101206 DCOM- 20110321 IS - 1478-3231 (Electronic) IS - 1478-3223 (Linking) VI - 31 IP - 1 DP - 2011 Jan TI - Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma. PG - 120-31 LID - 10.1111/j.1478-3231.2010.02359.x [doi] AB - BACKGROUND: GC33 is a recently developed monoclonal antibody against human glypican-3 (GPC3), which is significantly upregulated in hepatocellular carcinoma (HCC). GC33 recognizes a GPC3 ectodomain and shows significant antitumour activity in vivo. Thus, humanized GC33 antibody may be a promising tool for treating HCC having cell surface GPC3 expression. AIMS: This study aims to determine the specificity, subcellular localization and prognostic impact of GPC3 immunoreactivity detected by GC33 in HCC clinical specimens. METHODS: Immunohistochemical analysis was performed for 194 cases of resected HCC and prognostic analysis was performed for 185 eligible cases. Two antigen retrieval methods (autoclave and protease pretreatments) were used for immunohistochemistry and compared. The immunoscore system reflecting circumferential membranous GPC3 immunoreactivity was developed using either the autoclave or protease methods. The GPC3 mRNA level was analysed by quantitative real-time reverse transcription-polymerase chain reaction. RESULTS: GC33 immunostaining after autoclave is a sensitive method and revealed the GPC3 expression (>/=20% of tumour cells) in the majority (77%) of HCC samples tested. Alternatively, protease pretreatment showed lower sensitivity, but was superior for evaluating the intensity and subcellular localization of GPC3. Correlation between immunoscores and the GPC3 mRNA level was also confirmed. Subsequent clinicopathological analysis revealed worse prognoses in HCC patients with circumferential membranous GPC3 immunoreactivity. For HCC patients with hepatitis C virus (HCV) infection in particular, the high membranous GPC3 immunoreactivity was an independent prognostic factor for disease-free survival. CONCLUSIONS: Circumferential membranous GPC3 immunoreactivity in HCC indicates poorer prognosis particularly in patients with HCV infection. CI - (c) 2010 John Wiley & Sons A/S. AD - Section of Oncopathology and Regenerative Biology, Department of Pathology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. FAU - Yorita, Kenji AU - Yorita K FAU - Takahashi, Nobuyasu AU - Takahashi N FAU - Takai, Hirotake AU - Takai H FAU - Kato, Atsuhiko AU - Kato A FAU - Suzuki, Masami AU - Suzuki M FAU - Ishiguro, Takahiro AU - Ishiguro T FAU - Ohtomo, Toshihiko AU - Ohtomo T FAU - Nagaike, Koki AU - Nagaike K FAU - Kondo, Kazuhiro AU - Kondo K FAU - Chijiiwa, Kazuo AU - Chijiiwa K FAU - Kataoka, Hiroaki AU - Kataoka H LA - eng PT - Journal Article DEP - 20101021 PL - England TA - Liver Int JT - Liver international : official journal of the International Association for the Study of the Liver JID - 101160857 RN - 0 (GPC3 protein, human) RN - 0 (Glypicans) RN - 0 (RNA, Messenger) RN - 0 (Tumor Markers, Biological) SB - IM MH - Biopsy MH - Carcinoma, Hepatocellular/*chemistry/genetics/mortality/therapy/virology MH - Cell Membrane/*chemistry MH - Chi-Square Distribution MH - Disease-Free Survival MH - Female MH - Glypicans/*analysis/genetics MH - Hepacivirus/isolation & purification MH - Humans MH - *Immunohistochemistry MH - Japan MH - Kaplan-Meier Estimate MH - Liver Neoplasms/*chemistry/genetics/mortality/therapy/virology MH - Male MH - Middle Aged MH - Proportional Hazards Models MH - RNA, Messenger/analysis MH - Reverse Transcriptase Polymerase Chain Reaction MH - Risk Assessment MH - Risk Factors MH - Time Factors MH - Treatment Outcome MH - Tumor Markers, Biological/*analysis/genetics EDAT- 2010/10/23 06:00 MHDA- 2011/03/22 06:00 CRDT- 2010/10/23 06:00 PHST- 2010/10/21 [aheadofprint] AID - 10.1111/j.1478-3231.2010.02359.x [doi] PST - ppublish SO - Liver Int. 2011 Jan;31(1):120-31. doi: 10.1111/j.1478-3231.2010.02359.x. Epub 2010 Oct 21. PMID- 20961374 OWN - NLM STAT- MEDLINE DA - 20101021 DCOM- 20110321 IS - 1477-2574 (Electronic) IS - 1365-182X (Linking) VI - 12 IP - 9 DP - 2010 Nov TI - Resection margin in laparoscopic hepatectomy: a comparative study between wedge resection and anatomic left lateral sectionectomy. PG - 649-53 LID - 10.1111/j.1477-2574.2010.00221.x [doi] AB - BACKGROUND: Experience from open hepatectomy shows that anatomic liver resection achieves a better resection margin than wedge resection. In recent years, laparoscopic hepatectomy has increasingly been performed in patients with liver pathology including malignant lesions. Wedge resection (WR) and left lateral sectionectomy (LLS), which also represent non-anatomic and anatomic resection respectively, are the two most common types of laparoscopic hepatectomy performed. The aim of the present study was to compare the two types of laparoscopic hepatectomy with emphasis on resection margin. METHODS: Between November 2003 and July 2009, 44 consecutive patients who underwent laparoscopic hepatectomy were identified and retrospectively reviewed. The WR and LLS group of patients were compared in terms of operative outcomes, pathological findings, recurrence patterns and survival. RESULTS: Out of the 44 patients, 21 underwent LLS and 23 a WR. The two groups of patients were comparable in demographics. The two groups did not differ in conversion rate, blood loss, blood transfusion, mortality, morbidity and post-operative length of stay. The LLS group patients had significantly larger liver lesions, wider resection margin and less sub-centimetre margins. In patients with malignant liver lesions, there was no difference between the two groups in incidence of intra-hepatic recurrence and 3-year overall and disease-free survival. CONCLUSION: Operative outcomes are similar between laparoscopic WR and LLS. However, WR is less reliable than LLS in achieving a resection margin of more than 1 cm. Larger studies involving more patients with longer follow-up are warranted to determine the impact of the resection margin on intra-hepatic recurrence and survival. CI - (c) 2010 International Hepato-Pancreato-Biliary Association. AD - Division of Hepato-biliary and Pancreatic Surgery, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China. leekf@surgery.cuhk.edu.hk FAU - Lee, Kit-fai AU - Lee KF FAU - Wong, Jeff AU - Wong J FAU - Cheung, Yue-sun AU - Cheung YS FAU - Ip, Philip AU - Ip P FAU - Wong, John AU - Wong J FAU - Lai, Paul B S AU - Lai PB LA - eng PT - Comparative Study PT - Journal Article PL - England TA - HPB (Oxford) JT - HPB : the official journal of the International Hepato Pancreato Biliary Association JID - 100900921 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Blood Transfusion MH - Chi-Square Distribution MH - China MH - Disease-Free Survival MH - Female MH - Hepatectomy/adverse effects/*methods/mortality MH - Humans MH - Kaplan-Meier Estimate MH - *Laparoscopy/adverse effects/mortality MH - Length of Stay MH - Liver Neoplasms/mortality/pathology/*surgery MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Retrospective Studies MH - Risk Assessment MH - Risk Factors MH - Survival Rate MH - Time Factors MH - Treatment Outcome PMC - PMC2999793 OID - NLM: PMC2999793 [Available on 11/01/11] EDAT- 2010/10/22 06:00 MHDA- 2011/03/22 06:00 CRDT- 2010/10/22 06:00 PMCR- 2011/11/01 AID - 10.1111/j.1477-2574.2010.00221.x [doi] PST - ppublish SO - HPB (Oxford). 2010 Nov;12(9):649-53. doi: 10.1111/j.1477-2574.2010.00221.x. PMID- 20961373 OWN - NLM STAT- MEDLINE DA - 20101021 DCOM- 20110321 IS - 1477-2574 (Electronic) IS - 1365-182X (Linking) VI - 12 IP - 9 DP - 2010 Nov TI - Increasing time delay from presentation until surgical referral for hepatobiliary malignancies. PG - 644-8 LID - 10.1111/j.1477-2574.2010.00217.x [doi] AB - BACKGROUND: Studies have shown that delayed treatment of several non-hepatobiliary (HB) malignancies is associated with adverse effects on disease progression and survival. Delayed treatment of HB malignancies has not been thoroughly investigated. METHODS: We performed a retrospective institutional review of patients referred to the Hepatobiliary Surgery Service at Beth Israel Deaconess Medical Center (BIDMC) for hepatobiliary malignancies from 2002 to 2008. Primary outcomes included the time delays (TD) in patient workup. Secondary outcomes were reasons for delay as well as disparities in TD based on demographic factors. RESULTS: Multivariate-adjusted linear regression showed a significant trend of increasing time from presentation until referral to a HB surgeon over the 7-year period (P= 0.001). There were no differences in TD by gender, age or education level. Multivariate-adjusted linear regression showed a significant trend of increasing number of imaging tests performed prior to referral [computerized tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) and ultrasound and endoscopic ultrasound (US/EUS)] (P < 0.001). Multivariate-adjusted linear regression in resectable patients showed a significant difference in overall length of survival in those with a TD1 > 30 days compared with those with a TD1 (TD from presentation until referral) <30 days (P = 0.042). CONCLUSIONS: Delays were associated with an increase in imaging studies and delays adversely affect survival in resected patients. Referring physicians are encouraged to expedite the evaluation and early referral of all patients to an HB surgeon for evaluation and treatment. CI - (c) 2010 International Hepato-Pancreato-Biliary Association. AD - Center for Transplant Outcomes and Quality Improvement, The Transplant Institute at Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA. krisbelize@hotmail.com FAU - Croome, Kristopher P AU - Croome KP FAU - Chudzinski, Robyn AU - Chudzinski R FAU - Hanto, Douglas W AU - Hanto DW LA - eng PT - Journal Article PL - England TA - HPB (Oxford) JT - HPB : the official journal of the International Hepato Pancreato Biliary Association JID - 100900921 SB - IM MH - Biliary Tract Neoplasms/diagnosis/mortality/*surgery MH - Boston MH - *Digestive System Surgical Procedures MH - Endosonography MH - Female MH - Humans MH - Linear Models MH - Liver Neoplasms/diagnosis/mortality/*surgery MH - Logistic Models MH - Magnetic Resonance Imaging MH - Male MH - Middle Aged MH - Odds Ratio MH - Pancreatic Neoplasms/diagnosis/mortality/*surgery MH - Positron-Emission Tomography MH - *Referral and Consultation MH - Retrospective Studies MH - Risk Assessment MH - Risk Factors MH - Time Factors MH - Tomography, X-Ray Computed MH - Treatment Outcome PMC - PMC2999792 OID - NLM: PMC2999792 [Available on 11/01/11] EDAT- 2010/10/22 06:00 MHDA- 2011/03/22 06:00 CRDT- 2010/10/22 06:00 PMCR- 2011/11/01 AID - 10.1111/j.1477-2574.2010.00217.x [doi] PST - ppublish SO - HPB (Oxford). 2010 Nov;12(9):644-8. doi: 10.1111/j.1477-2574.2010.00217.x. PMID- 20961372 OWN - NLM STAT- MEDLINE DA - 20101021 DCOM- 20110321 IS - 1477-2574 (Electronic) IS - 1365-182X (Linking) VI - 12 IP - 9 DP - 2010 Nov TI - Longterm follow-up after transarterial chemotherapy for hepatocellular carcinoma in a Scandinavian centre. PG - 637-43 LID - 10.1111/j.1477-2574.2010.00210.x [doi] AB - BACKGROUND: Transarterial chemotherapy infusion (TAI) with lipiodol is a palliative treatment for hepatocellular carcinoma. The aim of this study was to describe the outcomes of TAI from a single scandinavian centre between 1995 to 2008. METHODS: The study is a retrospective analyse of prospectively collected data. TAI (doxorubicin, 50 mg with lipiodol) was administrated every 6 weeks. After 5 treatments, a CT scan was performed, and if the disease was stable, (RECIST score) treatment was continued. RESULTS: 57 patients with HCC were treated with TAI. Median age; 72 years (52-84), 41 (71%) men. 52 (91%) had Child-Pugh score A, and 5 (9%) had Child-Pugh B. Nine (16%) patients had a BCLC score A, 19 (33%) B, 29 (51%) C, while none was classified as BCLC D. Twenty nine (51%) patients had a tumour size >/= 10 cm. In total 254 treatments were performed, a median of 4 (1-20) per patient. Treatment mortality was 0%. In 30 (53%) patients the treatment strategy was not completed due to deteriorating clinical conditions. Median survival was 17 months (2-108), 2, 3, and 5-years survival was 34%, 22%, and 13%, respectively. Patients that responded to treatment (n = 23) had a median survival of 26 (13-108) months compared to 8 (2-48) months for those not fulfilling the treatment plan, p < 0.05. Tumour size >/= 10 cm, AFP >/= 400 microg/l, and Child-Pugh class B or C were negative prognostic factors for survival, p < 0.05. CONCLUSIONS: The 5 year survival was 13%, and median survival 17 months. Treatment mortality was 0%. Patients that responded to treatment (40%) had a median survival of 26 months. TAI provides good palliation but selection of patients is crucial. CI - (c) 2010 International Hepato-Pancreato-Biliary Association. AD - Department of Surgery Department of Radiology, Uppsala University, Uppsala, Sweden. agneta.noren@akademiska.se FAU - Noren, Agneta AU - Noren A FAU - Urdzik, Jozef AU - Urdzik J FAU - Duraj, Frans AU - Duraj F FAU - Barbier, Charlotte Ebeling AU - Barbier CE FAU - Karlson, Britt-Mari AU - Karlson BM FAU - Haglund, Ulf AU - Haglund U LA - eng PT - Journal Article DEP - 20100902 PL - England TA - HPB (Oxford) JT - HPB : the official journal of the International Hepato Pancreato Biliary Association JID - 100900921 RN - 0 (Antibiotics, Antineoplastic) RN - 23214-92-8 (Doxorubicin) RN - 8008-53-5 (Ethiodized Oil) SB - IM MH - Aged MH - Aged, 80 and over MH - Antibiotics, Antineoplastic/*administration & dosage/adverse effects MH - Carcinoma, Hepatocellular/mortality/radiography/*therapy MH - *Chemoembolization, Therapeutic/adverse effects MH - Doxorubicin/*administration & dosage/adverse effects MH - Ethiodized Oil/*administration & dosage/adverse effects MH - Female MH - Humans MH - Infusions, Intra-Arterial MH - Kaplan-Meier Estimate MH - Liver Neoplasms/mortality/radiography/*therapy MH - Male MH - Middle Aged MH - Palliative Care MH - Patient Selection MH - Registries MH - Retrospective Studies MH - Survival Rate MH - Sweden MH - Time Factors MH - Tomography, X-Ray Computed MH - Treatment Outcome PMC - PMC2999791 OID - NLM: PMC2999791 [Available on 11/01/11] EDAT- 2010/10/22 06:00 MHDA- 2011/03/22 06:00 CRDT- 2010/10/22 06:00 PMCR- 2011/11/01 PHST- 2010/09/02 [aheadofprint] AID - 10.1111/j.1477-2574.2010.00210.x [doi] PST - ppublish SO - HPB (Oxford). 2010 Nov;12(9):637-43. doi: 10.1111/j.1477-2574.2010.00210.x. Epub 2010 Sep 2. PMID- 20959822 OWN - NLM STAT- MEDLINE DA - 20101110 DCOM- 20110301 IS - 1532-1827 (Electronic) IS - 0007-0920 (Linking) VI - 103 IP - 10 DP - 2010 Nov 9 TI - Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. PG - 1542-7 AB - BACKGROUND: We assessed the effectiveness of cetuximab plus chronomodulated irinotecan, 5-fluorouracil (5-FU), leucovorin (FA) and oxaliplatin (L-OHP) (chrono-IFLO) administered as neoadjuvant chemotherapy to increase the resectability of colorectal liver metastases. METHODS: This was a phase II prospective trial with rate of liver metastases resection as primary end point. Forty-three patients with unresectable metastases were enroled: 9 with metastases >5 cm; 29 with multinodular (>4) disease; 1 with hilar location; 4 with extrahepatic lung disease. Treatment consisted of cetuximab at day 1 plus chronomodulated irinotecan 5-FU, FA and L-OHP for 2-6 days every 2 weeks. After the first 17 patients, doses were reduced for irinotecan to 110 mg m(2), 5-FU to 550 mg m(2) per day and L-OHP to 15 mg m(2) per day. RESULTS: Macroscopically complete resections were performed in 26 out of 43 patients (60%) after a median of 6 (range 3-15) cycles. Partial response was noticed in 34 patients (79%). Median overall survival was 37 months (95% CI: 21-53 months), with a 2-year survival of 68% in the entire population, 80.6% in resected patients and 47.1% in unresected patients (P=0.01). Grade 3/4 diarrhoea occurred in 93% and 36% of patients before and after dose reduction. CONCLUSION: Cetuximab plus chrono-IFLO achieved 60% complete resectability of colorectal liver metastases. AD - Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy. carlo.garufi@fastwebnet.it FAU - Garufi, C AU - Garufi C FAU - Torsello, A AU - Torsello A FAU - Tumolo, S AU - Tumolo S FAU - Ettorre, G M AU - Ettorre GM FAU - Zeuli, M AU - Zeuli M FAU - Campanella, C AU - Campanella C FAU - Vennarecci, G AU - Vennarecci G FAU - Mottolese, M AU - Mottolese M FAU - Sperduti, I AU - Sperduti I FAU - Cognetti, F AU - Cognetti F LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20101019 PL - England TA - Br J Cancer JT - British journal of cancer JID - 0370635 RN - 0 (Antibodies, Monoclonal) RN - 0 (Organoplatinum Compounds) RN - 0 (cetuximab) RN - 100286-90-6 (irinotecan) RN - 51-21-8 (Fluorouracil) RN - 58-05-9 (Leucovorin) RN - 63121-00-6 (oxaliplatin) RN - 7689-03-4 (Camptothecin) RN - EC 2.7.10.1 (Receptor, Epidermal Growth Factor) SB - IM MH - Adult MH - Aged MH - Antibodies, Monoclonal/adverse effects/*therapeutic use MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use MH - Camptothecin/administration & dosage/analogs & derivatives MH - Colorectal Neoplasms/*drug therapy/mortality/*secondary/surgery MH - Diarrhea/chemically induced MH - Disease-Free Survival MH - Female MH - Fluorouracil/administration & dosage MH - Hepatectomy MH - Humans MH - Leucovorin/administration & dosage MH - Liver Neoplasms/*pathology MH - Male MH - Middle Aged MH - Neoadjuvant Therapy/*methods MH - Organoplatinum Compounds/administration & dosage MH - Receptor, Epidermal Growth Factor/metabolism MH - Research Design MH - Survival Rate MH - Tomography, X-Ray Computed PMC - PMC2990583 OID - NLM: PMC2990583 [Available on 11/09/11] EDAT- 2010/10/21 06:00 MHDA- 2011/03/02 06:00 CRDT- 2010/10/21 06:00 PMCR- 2011/11/09 PHST- 2010/10/19 [aheadofprint] AID - 6605940 [pii] AID - 10.1038/sj.bjc.6605940 [doi] PST - ppublish SO - Br J Cancer. 2010 Nov 9;103(10):1542-7. Epub 2010 Oct 19. PMID- 20887327 OWN - NLM STAT- MEDLINE DA - 20101004 DCOM- 20110325 IS - 1477-2574 (Electronic) IS - 1365-182X (Linking) VI - 12 IP - 8 DP - 2010 Oct TI - Robotic versus laparoscopic resection of liver tumours. PG - 583-6 LID - 10.1111/j.1477-2574.2010.00234.x [doi] AB - BACKGROUND: There are scant data in the literature regarding the role of robotic liver surgery. The aim of the present study was to develop techniques for robotic liver tumour resection and to draw a comparison with laparoscopic resection. METHODS: Over a 1-year period, nine patients underwent robotic resection of peripherally located malignant lesions measuring <5 cm. These patients were compared prospectively with 23 patients who underwent laparoscopic resection of similar tumours at the same institution. Statistical analyses were performed using Student's t-test, chi(2) -test and Kaplan-Meier survival. All data are expressed as mean +/- SEM. RESULTS: The groups were similar with regards to age, gender and tumour type (P= NS). Tumour size was similar in both groups (robotic -3.2 +/- 1.3 cm vs. laparoscopic -2.9 +/- 1.3 cm, P= 0.6). Skin-to-skin operative time was 259 +/- 28 min in the robotic vs. 234 +/- 17 min in the laparoscopic group (P= 0.4). There was no difference between the two groups regarding estimated blood loss (EBL) and resection margin status. Conversion to an open operation was only necessary in one patient in the robotic group. Complications were observed in one patient in the robotic and four patients in the laparoscopic groups. The patients were followed up for a mean of 14 months and disease-free survival (DFS) was equivalent in both groups (P= 0.6). CONCLUSION: The results of this initial study suggest that, for selected liver lesions, a robotic approach provides similar peri-operative outcomes compared with laparoscopic liver resection (LLR). CI - (c) 2010 International Hepato-Pancreato-Biliary Association. AD - Endocrinology and Metabolism Institute, Cleveland Clinic, Cleveland, OH 44195, USA. berbere@ccf.org FAU - Berber, Eren AU - Berber E FAU - Akyildiz, Hizir Yakup AU - Akyildiz HY FAU - Aucejo, Federico AU - Aucejo F FAU - Gunasekaran, Ganesh AU - Gunasekaran G FAU - Chalikonda, Sricharan AU - Chalikonda S FAU - Fung, John AU - Fung J LA - eng PT - Comparative Study PT - Journal Article PL - England TA - HPB (Oxford) JT - HPB : the official journal of the International Hepato Pancreato Biliary Association JID - 100900921 SB - IM MH - Aged MH - Chi-Square Distribution MH - Disease-Free Survival MH - Female MH - Hepatectomy/adverse effects/*methods/mortality MH - Humans MH - Kaplan-Meier Estimate MH - *Laparoscopy/adverse effects/mortality MH - Liver Neoplasms/mortality/*surgery MH - Male MH - Middle Aged MH - Ohio MH - Risk Assessment MH - Risk Factors MH - *Robotics MH - *Surgery, Computer-Assisted/adverse effects/mortality MH - Time Factors MH - Treatment Outcome PMC - PMC2997665 OID - NLM: PMC2997665 [Available on 10/01/11] EDAT- 2010/10/05 06:00 MHDA- 2011/03/26 06:00 CRDT- 2010/10/05 06:00 PMCR- 2011/10/01 AID - 10.1111/j.1477-2574.2010.00234.x [doi] PST - ppublish SO - HPB (Oxford). 2010 Oct;12(8):583-6. doi: 10.1111/j.1477-2574.2010.00234.x. PMID- 20887322 OWN - NLM STAT- MEDLINE DA - 20101004 DCOM- 20110325 IS - 1477-2574 (Electronic) IS - 1365-182X (Linking) VI - 12 IP - 8 DP - 2010 Oct TI - Hepatic epithelioid haemangioendothelioma: is transplantation the only treatment option? PG - 546-53 LID - 10.1111/j.1477-2574.2010.00213.x [doi] AB - BACKGROUND: Hepatic epithelioid haemangioendothelioma (HEH) is a rare vascular neoplasm with unpredictable clinical behaviour. AIM: To compare overall survival (OS) and disease-free survival (DFS) between liver resection (LR) and orthotopic liver transplantation (OLT) for the treatment of HEH. METHODS: Retrospective review of 30 patients with HEH treated at Mayo Clinic during 1984 and 2007. RESULTS: Median age was 46 years with a female predominance of 2:1. Treatment included LR (n= 11), OLT (n= 11), chemotherapy (n= 5) and no treatment (n= 3). LR was associated with a 1-, 3- and 5-year OS of 100%, 86% and 86% and a DFS of 78%, 62% and 62%, respectively. OLT was associated with a 1-, 3- and 5-year OS of 91%, 73% and 73% and a DFS 64%, 46% and 46%, respectively. Metastases were present in 37% of patients but did not significantly affect OS. Important predictors of a favourable OS and DFS were largest tumour 30 [odds ratio (OR) = 4.17, confidence interval: 2.57-6.78, 12-month survival = 52.6%, c-statistic = 0.669], hyponatremia (OR = 2.07), and pre-OLT hemodialysis (OR = 2.35) were the main death risk factors. In alcoholic cirrhosis (n = 153, mean MELD = 21.1) and hepatocellular carcinoma (n = 123, mean MELD = 13.5), serum bilirubin and the survival after liver transplantation score were independent outcome parameters, respectively. MELD >30 currently represents a major risk factor for outcome. Risk factors differ in individual patient subgroups. In the current German practice of organ allocation to sicker patients, outcome prediction should be considered to prevent results below acceptable standards. CI - (c) 2010 The Authors. Transplant International (c) 2010 European Society for Organ Transplantation. AD - Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. FAU - Weismuller, Tobias J AU - Weismuller TJ FAU - Fikatas, Panagiotis AU - Fikatas P FAU - Schmidt, Jan AU - Schmidt J FAU - Barreiros, Ana P AU - Barreiros AP FAU - Otto, Gerd AU - Otto G FAU - Beckebaum, Susanne AU - Beckebaum S FAU - Paul, Andreas AU - Paul A FAU - Scherer, Markus N AU - Scherer MN FAU - Schmidt, Hartmut H AU - Schmidt HH FAU - Schlitt, Hans J AU - Schlitt HJ FAU - Neuhaus, Peter AU - Neuhaus P FAU - Klempnauer, Jurgen AU - Klempnauer J FAU - Pratschke, Johann AU - Pratschke J FAU - Manns, Michael P AU - Manns MP FAU - Strassburg, Christian P AU - Strassburg CP LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20100903 PL - England TA - Transpl Int JT - Transplant international : official journal of the European Society for Organ Transplantation JID - 8908516 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Carcinoma, Hepatocellular/surgery MH - End Stage Liver Disease/*surgery MH - Female MH - Germany MH - Health Care Rationing/methods MH - Humans MH - Liver Neoplasms/surgery MH - *Liver Transplantation MH - Male MH - Middle Aged MH - Reoperation MH - Retrospective Studies MH - Risk Factors MH - Severity of Illness Index MH - Survival Analysis MH - Tissue and Organ Procurement MH - Treatment Outcome EDAT- 2010/09/08 06:00 MHDA- 2011/03/18 06:00 CRDT- 2010/09/08 06:00 PHST- 2010/09/03 [aheadofprint] AID - TRI1161 [pii] AID - 10.1111/j.1432-2277.2010.01161.x [doi] PST - ppublish SO - Transpl Int. 2011 Jan;24(1):91-9. doi: 10.1111/j.1432-2277.2010.01161.x. Epub 2010 Sep 3. PMID- 20804364 OWN - NLM STAT- MEDLINE DA - 20100831 DCOM- 20110303 IS - 1557-7708 (Electronic) IS - 1075-5535 (Linking) VI - 16 IP - 5 DP - 2010 May TI - Use of Chinese Medicine among patients with liver cancer in Taiwan. PG - 527-8 FAU - Lin, Yi-Hsien AU - Lin YH FAU - Chiu, Jen-Hwey AU - Chiu JH LA - eng PT - Letter PL - United States TA - J Altern Complement Med JT - Journal of alternative and complementary medicine (New York, N.Y.) JID - 9508124 SB - IM MH - Acupuncture Therapy/utilization MH - Adult MH - Aged MH - Complementary Therapies/*utilization MH - Female MH - Humans MH - Liver Neoplasms/*therapy MH - Male MH - Medicine, Chinese Traditional/*utilization MH - Middle Aged MH - Musculoskeletal Manipulations/utilization MH - Phytotherapy/utilization MH - Retrospective Studies MH - Taiwan EDAT- 2010/09/02 06:00 MHDA- 2011/03/04 06:00 CRDT- 2010/09/01 06:00 AID - 10.1089/acm.2009.0637 [doi] PST - ppublish SO - J Altern Complement Med. 2010 May;16(5):527-8. PMID- 20713493 OWN - NLM STAT- MEDLINE DA - 20101004 DCOM- 20110310 IS - 1078-0432 (Print) IS - 1078-0432 (Linking) VI - 16 IP - 19 DP - 2010 Oct 1 TI - New strategies in hepatocellular carcinoma: genomic prognostic markers. PG - 4688-94 AB - Accurate prognosis prediction in oncology is critical. In patients with hepatocellular carcinoma (HCC), unlike most solid tumors, the coexistence of two life-threatening conditions, cancer and cirrhosis, makes prognostic assessments difficult. Despite the usefulness of clinical staging systems for HCC in routine clinical decision making (e.g., Barcelona-Clinic Liver Cancer algorithm), there is still a need to refine and complement outcome predictions. Recent data suggest the ability of gene signatures from the tumor (e.g., EpCAM signature) and adjacent tissue (e.g., poor-survival signature) to predict outcome in HCC (either recurrence or overall survival), although independent external validation is still required. In addition, novel information is being produced by alternative genomic sources such as microRNA (miRNA; e.g., miR-26a) or epigenomics, areas in which promising preliminary data are thoroughly explored. Prognostic models need to contemplate the impact of liver dysfunction and risk of subsequent de novo tumors in a patient's life expectancy. The challenge for the future is to precisely depict genomic predictors (e.g., gene signatures, miRNA, or epigenetic biomarkers) at each stage of the disease and their specific influence to determine patient prognosis. CI - (c)2010 AACR. AD - Institut d'Investigacions Biomediques Agusto Pi i Sunyer, Hospital Clinic, Barcelona, Spain. FAU - Villanueva, Augusto AU - Villanueva A FAU - Hoshida, Yujin AU - Hoshida Y FAU - Toffanin, Sara AU - Toffanin S FAU - Lachenmayer, Anja AU - Lachenmayer A FAU - Alsinet, Clara AU - Alsinet C FAU - Savic, Radoslav AU - Savic R FAU - Cornella, Helena AU - Cornella H FAU - Llovet, Josep M AU - Llovet JM LA - eng GR - 1R01DK076986-01/DK/NIDDK NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20100816 PL - United States TA - Clin Cancer Res JT - Clinical cancer research : an official journal of the American Association for Cancer Research JID - 9502500 RN - 0 (Genetic Markers) RN - 0 (Tumor Markers, Biological) SB - IM MH - Carcinoma, Hepatocellular/*diagnosis/*genetics MH - Genetic Markers/genetics MH - Humans MH - Liver Neoplasms/*diagnosis/*genetics MH - Predictive Value of Tests MH - Prognosis MH - Treatment Outcome MH - Tumor Markers, Biological/*genetics EDAT- 2010/08/18 06:00 MHDA- 2011/03/11 06:00 CRDT- 2010/08/18 06:00 PHST- 2010/08/16 [aheadofprint] PHST- 2010/09/28 [aheadofprint] AID - 1078-0432.CCR-09-1811 [pii] AID - 10.1158/1078-0432.CCR-09-1811 [doi] PST - ppublish SO - Clin Cancer Res. 2010 Oct 1;16(19):4688-94. Epub 2010 Aug 16. PMID- 20709617 OWN - NLM STAT- MEDLINE DA - 20100927 DCOM- 20110228 IS - 1878-7886 (Electronic) VI - 147 IP - 3 DP - 2010 Jun TI - Liver resection for intrahepatic stones in congenital bile duct dilatation. PG - e175-80 AB - OBJECTIVE: This study reports our clinical experience with liver resection for congenital dilatation of the intrahepatic bile duct and intrahepatic gallstones to evaluate results and define indications for treatment. PATIENTS AND METHODS: We studied the clinical data of patients who underwent hepatic resection for intrahepatic lithiasis from January 1992 to December 2008 and assessed the immediate and long-term results of these interventions. RESULTS: Of 49 treated patients, 47 underwent liver resection. In the majority of cases, the disease was limited to the left lobe and left hepatectomy was the most commonly performed surgical procedure. The operative mortality was zero with morbidity in 24.5% of patients. Cholangiocarcinoma was diagnosed in six cases (12.2%). In 91.6% of cases the long-term results were good or satisfactory. CONCLUSION: Treatment goals in all cases should be the elimination of intrahepatic stones, the prevention of recurrent lithiasis, and prevention or cure of cholangiocarcinoma. Surgical excision is the best possible treatment for symptomatic patients with localized disease and atrophy of the affected liver. CI - Copyright (c) 2010. Published by Elsevier Masson SAS. AD - Department of Hepatobiliary Surgery, Faculty of Medicine and Surgery, A. Gemelli, Catholic University of Sacred Heart, Rome, Italy. gclemente@rm.unicatt.it FAU - Clemente, G AU - Clemente G FAU - Giuliante, F AU - Giuliante F FAU - De Rose, A M AU - De Rose AM FAU - Ardito, F AU - Ardito F FAU - Giovannini, I AU - Giovannini I FAU - Nuzzo, G AU - Nuzzo G LA - eng PT - Journal Article DEP - 20100814 PL - France TA - J Visc Surg JT - Journal of visceral surgery JID - 101532664 SB - IM MH - Adult MH - Aged MH - Bile Duct Neoplasms/diagnosis/pathology/prevention & control/surgery MH - Bile Ducts, Intrahepatic/*abnormalities/*surgery MH - Caroli Disease/*surgery MH - Cholangiocarcinoma/diagnosis/pathology/prevention & control/surgery MH - Female MH - Gallstones/*surgery MH - Hepatectomy/*methods MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Postoperative Complications/mortality MH - Retrospective Studies MH - Survival Rate EDAT- 2010/08/17 06:00 MHDA- 2011/03/01 06:00 CRDT- 2010/08/17 06:00 PHST- 2010/08/14 [aheadofprint] AID - S1878-7886(10)00041-X [pii] AID - 10.1016/j.jviscsurg.2010.06.005 [doi] PST - ppublish SO - J Visc Surg. 2010 Jun;147(3):e175-80. Epub 2010 Aug 14. PMID- 20662790 OWN - NLM STAT- MEDLINE DA - 20100728 DCOM- 20110325 IS - 1477-2574 (Electronic) IS - 1365-182X (Linking) VI - 12 IP - 6 DP - 2010 Aug TI - Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy. PG - 396-402 AB - OBJECTIVES: Cholangiocarcinoma (CCA) has a poor prognosis and its aetiology is inadequately understood. Magnetic resonance spectroscopy (MRS) of bile may provide insights into the pathogenesis of CCA and help identify novel diagnostic biomarkers. The aim of this study was to compare the chemical composition of bile from patients with CCA with that of bile from patients with benign biliary disease. METHODS: Magnetic resonance spectra were acquired from the bile of five CCA patients and compared with MRS of control bile from patients with benign biliary disease (seven with gallstones, eight with sphincter of Oddi dysfunction [SOD], five with primary sclerosing cholangitis [PSC]). Metabolic profiles were compared using both univariate and multivariate pattern-recognition analysis. RESULTS: Univariate analysis showed that levels of glycine-conjugated bile acids were significantly increased in patients with CCA, compared with the benign disease groups (P= 0.002). 7 beta primary bile acids were significantly increased (P= 0.030) and biliary phosphatidylcholine (PtC) levels were reduced (P= 0.010) in bile from patients with CCA compared with bile from gallstone patients. These compounds were also of primary importance in the multivariate analysis: the cohorts were differentiated by partial least squares discriminant analysis (PLS-DA). CONCLUSIONS: These preliminary data suggest that altered bile acid and PtC metabolism play an important role in CCA aetiopathogenesis and that specific metabolites may have potential as future biomarkers. AD - Hepatology and Gastroenterology Section, Department of Medicine, Imperial College London, London, UK. amar.sharif@imperial.ac.uk FAU - Sharif, Amar W AU - Sharif AW FAU - Williams, Horace R T AU - Williams HR FAU - Lampejo, Temi AU - Lampejo T FAU - Khan, Shahid A AU - Khan SA FAU - Bansi, Devinder S AU - Bansi DS FAU - Westaby, David AU - Westaby D FAU - Thillainayagam, Andrew V AU - Thillainayagam AV FAU - Thomas, Howard C AU - Thomas HC FAU - Cox, I Jane AU - Cox IJ FAU - Taylor-Robinson, Simon D AU - Taylor-Robinson SD LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - HPB (Oxford) JT - HPB : the official journal of the International Hepato Pancreato Biliary Association JID - 100900921 RN - 0 (Bile Acids and Salts) RN - 0 (Phosphatidylcholines) RN - 0 (Tumor Markers, Biological) RN - 56-40-6 (Glycine) SB - IM MH - Aged MH - Aged, 80 and over MH - Algorithms MH - Bile/*metabolism MH - Bile Acids and Salts/metabolism MH - Bile Duct Neoplasms/*metabolism/pathology MH - Bile Ducts, Intrahepatic/*metabolism/pathology MH - Case-Control Studies MH - Cholangiocarcinoma/*metabolism/pathology MH - Female MH - Glycine/analogs & derivatives/metabolism MH - Humans MH - London MH - *Magnetic Resonance Spectroscopy MH - Male MH - Metabolomics/*methods MH - Middle Aged MH - Multivariate Analysis MH - Pattern Recognition, Automated MH - Phosphatidylcholines/metabolism MH - Principal Component Analysis MH - Prognosis MH - Tumor Markers, Biological/*metabolism PMC - PMC3028580 OID - NLM: PMC3028580 [Available on 08/01/11] EDAT- 2010/07/29 06:00 MHDA- 2011/03/26 06:00 CRDT- 2010/07/29 06:00 PMCR- 2011/08/01 AID - HPB185 [pii] AID - 10.1111/j.1477-2574.2010.00185.x [doi] PST - ppublish SO - HPB (Oxford). 2010 Aug;12(6):396-402. PMID- 20662788 OWN - NLM STAT- MEDLINE DA - 20100728 DCOM- 20110325 IS - 1477-2574 (Electronic) IS - 1365-182X (Linking) VI - 12 IP - 6 DP - 2010 Aug TI - A review of factors predicting perioperative death and early outcome in hepatopancreaticobiliary cancer surgery. PG - 380-8 AB - OBJECTIVES: In the context of comparisons of surgical outcomes, risk adjustment is the retrospective adjustment of a provider's or a surgeon's results for case mix and/or hospital volume. It allows accurate, meaningful inter-provider comparison. It is therefore an essential component of any audit and quality improvement process. The aim of this study was to review the literature to identify those factors known to affect prognosis in hepatobiliary and pancreatic cancer surgery. METHODS: PubMed was used to identify studies assessing risk in patients undergoing resection surgery, rather than bypass surgery, for hepatobiliary and pancreatic cancer. RESULTS: In total, 63 and 68 papers, pertaining to 24 609 and 63 654 patients who underwent hepatic or pancreatic resection for malignancy, respectively, were identified. Overall, 22 generic preoperative factors predicting outcome on multivariate analysis, including demographics, blood results, preoperative biliary drainage and co-morbidities, were identified, with tumour characteristics proving disease-specific factors. Operative duration, transfusion, operative extent, vascular resection and additional intra-abdominal procedures were also found to be predictive of early outcome. CONCLUSIONS: The development of a risk adjustment model will allow for the identification of those factors with most influence on early outcome and will thus identify potential targets for preoperative optimization and allow for the development of a multicentre risk prediction model. AD - Department of Hepatobiliary and Pancreatic Surgery, University Hospitals of Leicester, Leicester General Hospital, Leicester, UK. chris.mann@doctors.org.uk FAU - Mann, Chris D AU - Mann CD FAU - Palser, Tom AU - Palser T FAU - Briggs, Chris D AU - Briggs CD FAU - Cameron, Iain AU - Cameron I FAU - Rees, Myrrdin AU - Rees M FAU - Buckles, John AU - Buckles J FAU - Berry, David P AU - Berry DP LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - England TA - HPB (Oxford) JT - HPB : the official journal of the International Hepato Pancreato Biliary Association JID - 100900921 SB - IM MH - Biliary Tract Neoplasms/mortality/*surgery MH - Decision Support Techniques MH - Digestive System Surgical Procedures/*mortality MH - Humans MH - Liver Neoplasms/mortality/*surgery MH - Pancreatic Neoplasms/mortality/*surgery MH - Patient Selection MH - Risk Assessment MH - Risk Factors MH - Treatment Outcome PMC - PMC3028578 OID - NLM: PMC3028578 [Available on 08/01/11] EDAT- 2010/07/29 06:00 MHDA- 2011/03/26 06:00 CRDT- 2010/07/29 06:00 PMCR- 2011/08/01 AID - HPB179 [pii] AID - 10.1111/j.1477-2574.2010.00179.x [doi] PST - ppublish SO - HPB (Oxford). 2010 Aug;12(6):380-8. PMID- 20645090 OWN - NLM STAT- MEDLINE DA - 20101005 DCOM- 20110317 IS - 1432-2323 (Electronic) IS - 0364-2313 (Linking) VI - 34 IP - 11 DP - 2010 Nov TI - Percutaneous radiofrequency ablation versus partial hepatectomy for multicentric small hepatocellular carcinomas: a nonrandomized comparative study. PG - 2671-6 AB - BACKGROUND: The aim of this study was to compare the results of percutaneous radiofrequency ablation (RFA) with those of partial hepatectomy (PH) in the treatment of multicentric small hepatocellular carcinomas (HCCs). With advances in RFA, it is not known whether the minimally invasive approach with percutaneous RFA could attain comparable survival outcomes but with a lower morbidity in patients with multicentric HCCs. METHODS: From January 2002 and December 2007, 159 patients who had two or three HCCs, with the largest tumor no more than 5 cm in diameter, had no major vascular invasion or extrahepatic metastases, and were treated with either PH (n = 73) or RFA (n = 86) were included in the study. RESULTS: There was no procedure-related mortality in both groups of patients. Major complications happened significantly more often after PH than after RFA (19.2 vs. 8.1%). The hospital stay was significantly longer after PH than after RFA (median = 9 vs. 3 days). The 1-, 3-, and 5-year overall survival rates for the PH and RFA groups were 91.8, 68.7, 44.5% and 94.2, 64.4, 21.2%, respectively. The corresponding disease-free survival rates for the two groups were 62.1, 33.6, 3.6% and 29.4, 2.7, 0%, respectively. The PH group had significantly longer overall survival and disease-free survival than the RFA group. CONCLUSIONS: PH resulted in better survival outcomes than RFA for patients with multicentric small HCCs. However, RFA had the benefits of lower procedure-related morbidity and shorter hospital stay. AD - Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, No. 225 Changhai Road, 200438, Shanghai, China. FAU - Guo, Wei-Xing AU - Guo WX FAU - Zhai, Bo AU - Zhai B FAU - Lai, Eric C H AU - Lai EC FAU - Li, Nan AU - Li N FAU - Shi, Jie AU - Shi J FAU - Lau, Wan-Yee AU - Lau WY FAU - Wu, Meng-Chao AU - Wu MC FAU - Cheng, Shu-Qun AU - Cheng SQ LA - eng PT - Clinical Trial PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - World J Surg JT - World journal of surgery JID - 7704052 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Carcinoma, Hepatocellular/mortality/*surgery MH - *Catheter Ablation MH - Female MH - *Hepatectomy MH - Humans MH - Liver Neoplasms/mortality/*surgery MH - Male MH - Middle Aged MH - Survival Analysis MH - Young Adult EDAT- 2010/07/21 06:00 MHDA- 2011/03/18 06:00 CRDT- 2010/07/21 06:00 AID - 10.1007/s00268-010-0732-9 [doi] PST - ppublish SO - World J Surg. 2010 Nov;34(11):2671-6. PMID- 20607255 OWN - NLM STAT- MEDLINE DA - 20101005 DCOM- 20110317 IS - 1432-2323 (Electronic) IS - 0364-2313 (Linking) VI - 34 IP - 11 DP - 2010 Nov TI - Survival benefit of hepatopancreatoduodenectomy for cholangiocarcinoma in comparison to hepatectomy or pancreatoduodenectomy. PG - 2662-70 AB - BACKGROUND: Perihilar and distal cholangiocarcinoma remain difficult to treat, and long-term survival is poor. We conducted a retrospective study of patients with cholangiocarcinoma to examine whether hepatopancreatoduodenectomy, in comparison to standard surgeries, provides a survival benefit. METHODS: Subjects were 75 patients with perihilar or distal cholangiocarcinoma who, between April 1997 and May 2007, underwent hepatectomy with bile duct resection (Hx, n = 29), pancreatoduodenectomy (PD, n = 32), or hepatopancreatoduodenectomy (HPD, n = 14) at our hospital. We compared surgical outcomes and survival between groups and identified factors negatively influencing survival. RESULTS: Morbidity and in-hospital mortality did not differ significantly between groups (Hx group, 34% and 10%, respectively; PD group, 44% and 3%; and HPD, 57% and 0%). The overall median survival time was 39 months, and overall 5-year survival (including in-hospital mortality) was 42%. Respective group values were as follows: Hx, 24 months and 31%; PD, 51 months and 49%, and HPD, 63 months and 50%. Although the number of patients was small, survival in the HPD was not influenced by the type of invasion whether widespread intramural invasion (n = 8), superficial spread (n = 4), or hepatoduodenal ligament invasion (n = 2). Multivariate analysis (Cox proportional hazards model) showed only perineural invasion (p = .007) and decreased curability (R1/2 resection) (p = .017) to be independent risk factors influencing survival. CONCLUSIONS: In cases of perihilar or distal cholangiocarcinoma, aggressive surgery must be aimed at overcoming perineural invasion. Our findings indicate that HPD improves survival of patients undergoing surgery for widespread cholangiocarcinoma in comparison to standard surgeries. AD - Department of Surgery, Ogaki Municipal Hospital, 4-86 Minaminokawa-cho, Ogaki, 503-8502, Japan. y-kaneoka@omh.ogaki.gifu.jp FAU - Kaneoka, Yuji AU - Kaneoka Y FAU - Yamaguchi, Akihiro AU - Yamaguchi A FAU - Isogai, Masatoshi AU - Isogai M FAU - Kumada, Takashi AU - Kumada T LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - World J Surg JT - World journal of surgery JID - 7704052 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Bile Duct Neoplasms/*surgery MH - *Bile Ducts, Intrahepatic MH - Cholangiocarcinoma/*surgery MH - Female MH - Hepatectomy/*mortality MH - Humans MH - Male MH - Middle Aged MH - Pancreaticoduodenectomy/*mortality MH - Retrospective Studies MH - Survival Analysis EDAT- 2010/07/08 06:00 MHDA- 2011/03/18 06:00 CRDT- 2010/07/08 06:00 AID - 10.1007/s00268-010-0702-2 [doi] PST - ppublish SO - World J Surg. 2010 Nov;34(11):2662-70. PMID- 20558918 OWN - NLM STAT- MEDLINE DA - 20100618 DCOM- 20110308 IS - 1349-7235 (Electronic) IS - 0918-2918 (Linking) VI - 49 IP - 12 DP - 2010 TI - Antibiotic prophylaxis in transcatheter treatment of hepatocellular carcinoma: an open randomized prospective study of oral versus intravenous administration. PG - 1059-65 AB - BACKGROUND: Transcatheter arterial chemoembolization (TACE) and transcatheter arterial infusion chemotherapy (TAI) are increasingly used to treat inoperable liver malignancies. It has not been determined whether standard oral and intravenous administration of antibiotics have different prophylactic effects against post-TACE/TAI infection. We compared the efficacy of oral levofloxacin (LVFX) and intravenous cephazolin (CEZ) in patients receiving TACE/TAI for hepatocellular carcinoma (HCC) using a prospective design. PATIENTS AND METHODS: One hundred twenty-nine eligible subjects with HCC treated by TACE/TAI were analyzed in this study. Patients were randomly assigned by the envelope method to groups who received either intravenous infusion of CEZ at 2 g/day or oral administration of LVFX at 300 mg/day for 5 days. Laboratory data, changes in antibiotic administration from the standard ones, duration of hospital stay, side effects of antibiotics, and infectious complications were assessed. RESULTS: There were no significant differences in the WBC counts and serum CRP levels between the groups; there were also no significant inter-group differences in the numbers of infectious and other adverse events. CONCLUSION: Our study findings suggest that the results of peroral administration of LVFX for the prevention of post-procedure infectious complications in patients receiving TACE/TAI for HCC are not inferior to those of intravenous administration of CEZ. AD - Department of Gastroenterology, Hyogo Prefectural Awaji Hospital, Sumoto, Japan. FAU - Ebisutani, Chikara AU - Ebisutani C FAU - Sato, Shuichi AU - Sato S FAU - Nishi, Katsuhisa AU - Nishi K FAU - Inoue, Hiroshi AU - Inoue H FAU - Yoshie, Tomoo AU - Yoshie T FAU - Kinoshita, Yoshikazu AU - Kinoshita Y LA - eng PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial DEP - 20100615 PL - Japan TA - Intern Med JT - Internal medicine (Tokyo, Japan) JID - 9204241 RN - 0 (Inflammation Mediators) RN - 25953-19-9 (Cefazolin) RN - 82419-36-1 (Ofloxacin) SB - IM MH - Administration, Oral MH - Aged MH - Aged, 80 and over MH - Antibiotic Prophylaxis/*methods MH - Carcinoma, Hepatocellular/blood/*drug therapy/surgery MH - Cefazolin/administration & dosage MH - Chemoembolization, Therapeutic/methods MH - Female MH - Humans MH - Inflammation Mediators/blood MH - Infusions, Intra-Arterial MH - Infusions, Intravenous MH - Liver Neoplasms/blood/*drug therapy/surgery MH - Male MH - Middle Aged MH - Ofloxacin/administration & dosage MH - Postoperative Complications/etiology/microbiology/*prevention & control MH - Prospective Studies MH - Treatment Outcome EDAT- 2010/06/19 06:00 MHDA- 2011/03/09 06:00 CRDT- 2010/06/19 06:00 PHST- 2010/06/15 [epublish] AID - JST.JSTAGE/internalmedicine/49.3173 [pii] PST - ppublish SO - Intern Med. 2010;49(12):1059-65. Epub 2010 Jun 15. PMID- 20558916 OWN - NLM STAT- MEDLINE DA - 20100618 DCOM- 20110308 IS - 1349-7235 (Electronic) IS - 0918-2918 (Linking) VI - 49 IP - 12 DP - 2010 TI - Antibiotic prophylaxis and the clinical meaning after transcatheter treatment for hepatocellular carcinoma: indicated? PG - 1049-50 FAU - Ishikawa, Toru AU - Ishikawa T LA - eng PT - Editorial DEP - 20100615 PL - Japan TA - Intern Med JT - Internal medicine (Tokyo, Japan) JID - 9204241 SB - IM MH - Antibiotic Prophylaxis/*methods MH - Carcinoma, Hepatocellular/*drug therapy/surgery MH - *Catheterization/adverse effects MH - *Chemoembolization, Therapeutic/adverse effects MH - Humans MH - Infusions, Intra-Arterial MH - Liver Neoplasms/*drug therapy/surgery MH - Treatment Outcome EDAT- 2010/06/19 06:00 MHDA- 2011/03/09 06:00 CRDT- 2010/06/19 06:00 PHST- 2010/06/15 [epublish] AID - JST.JSTAGE/internalmedicine/49.3642 [pii] PST - ppublish SO - Intern Med. 2010;49(12):1049-50. Epub 2010 Jun 15. PMID- 20496000 OWN - NLM STAT- MEDLINE DA - 20110113 DCOM- 20110321 IS - 1573-3610 (Electronic) IS - 0094-5145 (Linking) VI - 36 IP - 1 DP - 2011 Feb TI - Chumnguh thleum: understanding liver illness and hepatitis B among Cambodian immigrants. PG - 27-34 AB - Cambodian immigrants are over 25 times more likely to have evidence of chronic hepatitis B infection than the general US population. Carriers of HBV are over 100 times more likely to develop liver cancer than non-carriers. Liver cancer incidence is the second leading cancer for Cambodian men and the sixth for Cambodian women. Despite this, this underserved population has received very little attention from health disparities researchers. Culturally and linguistically appropriate interventions are necessary to increase hepatitis B knowledge, serologic testing, and vaccination among Cambodian Americans. Eight group interviews were held with Cambodian American men (48) and women (49). Focus group discussion revealed unanticipated information about sociocultural influences on participants' understanding about hepatitis B transmission, disease course, and prevention and treatment informed by humoral theories underlying Khmer medicine, by biomedicine, and by migration experiences. Our findings reveal the value of qualitative exploration to providing cultural context to biomedical information--a formula for effective health promotion and practice. AD - Helen Diller Family Comprehensive Cancer Center and Department of Anthropology, History, and Social Medicine, University of California, San Francisco, 1450 3rd Street, MC 0128, PO Box 589001, San Francisco, CA 94158-9001, USA. nburke@cc.ucsf.edu FAU - Burke, Nancy J AU - Burke NJ FAU - Do, Hoai Huyen AU - Do HH FAU - Talbot, Jocelyn AU - Talbot J FAU - Sos, Channdara AU - Sos C FAU - Svy, Danika AU - Svy D FAU - Taylor, Victoria M AU - Taylor VM LA - eng PT - Journal Article PT - Randomized Controlled Trial PL - Netherlands TA - J Community Health JT - Journal of community health JID - 7600747 SB - IM MH - Adult MH - Aged MH - Cambodia/ethnology MH - Community-Based Participatory Research MH - *Cultural Competency MH - Emigrants and Immigrants/*psychology/statistics & numerical data MH - Female MH - Focus Groups MH - *Health Knowledge, Attitudes, Practice MH - Health Promotion/*methods MH - *Health Status Disparities MH - Hepatitis B/diagnosis/*ethnology/prevention & control MH - Humans MH - Liver Neoplasms/*ethnology/prevention & control/virology MH - Male MH - Mass Screening/utilization MH - Middle Aged MH - Qualitative Research MH - United States/epidemiology MH - Vaccination MH - Young Adult PMC - PMC3020312 OID - NLM: PMC3020312 EDAT- 2010/05/25 06:00 MHDA- 2011/03/22 06:00 CRDT- 2010/05/25 06:00 AID - 10.1007/s10900-010-9277-y [doi] PST - ppublish SO - J Community Health. 2011 Feb;36(1):27-34. PMID- 20177362 OWN - NLM STAT- MEDLINE DA - 20110128 DCOM- 20110308 IS - 1537-453X (Electronic) IS - 0277-3732 (Linking) VI - 34 IP - 1 DP - 2011 Feb TI - Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301). PG - 58-62 AB - OBJECTIVES: No established therapy exists for unresectable intrahepatic cholangiocarcinoma (ICC). We conducted a phase I/II study to ascertain the recommended dose (RD) of hepatic arterial infusion using gemcitabine (GEM) for ICC and to assess the efficacy and safety. METHODS: For patients with unresectable ICC, GEM was administered through the hepatic artery via the port system as a 30-minute infusion on days 1, 8, and 15 every 4 weeks for 5 cycles. In phase I, dosage for levels 1, 2, and 3 was set at 600, 800, and 1000 mg/m, respectively, and was increased in 3 to 6 patients at a time. Maximum tolerated dose was defined as a dosage resulting in dose-limiting toxicity in 2 of 3 patients or 3 of 6 patients, and RD was estimated during the first cycle. In the phase II, more RD patients were added to assess tumor response and toxicity. RESULTS: During the phase I, 16 patients were enrolled. Maximum tolerated dose was not reached. Assuming RD at 1000 mg/m, the phase II enrolled a total of 13 patients. The following Grade 3 toxicities were observed: neutropenia 20%, increased gamma-glutamyl transpeptidase 8%, increased aspartate aminotransferase 4%, increased alanine aminotransferase 4%, increased bilirubin 4%, nausea 4%, and fatigue 4%. The tumor response rate was 7.7% (complete response 0, partial response 1, stable disease 8, and progressive disease 4). CONCLUSION: Whereas the toxicity of hepatic arterial infusion with 1000 mg/m GEM for ICC was tolerable, expected efficacy could not be obtained, thus suggesting only minimal activity. AD - Aichi Cancer Center Hospital, Nagoya, Japan. 105824@aichi-cc.jp FAU - Inaba, Yoshitaka AU - Inaba Y FAU - Arai, Yasuaki AU - Arai Y FAU - Yamaura, Hidekazu AU - Yamaura H FAU - Sato, Yozo AU - Sato Y FAU - Najima, Mina AU - Najima M FAU - Aramaki, Takeshi AU - Aramaki T FAU - Sone, Miyuki AU - Sone M FAU - Kumada, Takashi AU - Kumada T FAU - Tanigawa, Noboru AU - Tanigawa N FAU - Anai, Hiroshi AU - Anai H FAU - Yoshioka, Tetsuya AU - Yoshioka T FAU - Ikeda, Masafumi AU - Ikeda M CN - Japan Interventional Radiology in Oncology Study Group (JIVROSG) LA - eng PT - Clinical Trial, Phase I PT - Clinical Trial, Phase II PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't PL - United States TA - Am J Clin Oncol JT - American journal of clinical oncology JID - 8207754 RN - 0 (Antimetabolites, Antineoplastic) RN - 103882-84-4 (gemcitabine) RN - 951-77-9 (Deoxycytidine) RN - Intrahepatic cholangiocarcinoma SB - IM MH - Adult MH - Aged MH - Antimetabolites, Antineoplastic/*therapeutic use MH - Bile Duct Neoplasms/drug therapy/pathology/surgery MH - Bile Ducts, Intrahepatic/*drug effects/pathology/surgery MH - Cholangiocarcinoma/drug therapy/pathology/surgery MH - Deoxycytidine/*analogs & derivatives/therapeutic use MH - Female MH - Hepatic Artery MH - Humans MH - Infusions, Intra-Arterial MH - Liver Neoplasms/drug therapy/pathology/surgery MH - Male MH - Maximum Tolerated Dose MH - Middle Aged MH - Neoplasm Staging MH - Survival Rate MH - Treatment Outcome EDAT- 2010/02/24 06:00 MHDA- 2011/03/09 06:00 CRDT- 2010/02/24 06:00 AID - 10.1097/COC.0b013e3181d2709a [doi] PST - ppublish SO - Am J Clin Oncol. 2011 Feb;34(1):58-62. PMID- 19427630 OWN - NLM STAT- MEDLINE DA - 20110126 DCOM- 20110228 IS - 1879-1883 (Electronic) IS - 0002-9610 (Linking) VI - 201 IP - 2 DP - 2011 Feb TI - Intrahepatic cholangiocarcinoma: analysis of 44 consecutive resected cases including 5 cases with repeat resections. PG - 203-8 AB - BACKGROUND: Prognosis after resection for intrahepatic cholangiocarcinoma (ICC) remains unsatisfactory. There remains no effective therapy after recurrent ICC. OBJECTIVE: The current study sought to evaluate risk factors associated with recurrent ICC and possible therapies after resection. METHOD: A review of data from patients who underwent potentially curative resection for ICC was performed. RESULTS: A total of 44 potentially curative resections were performed from 1995 to 2008. Mortality was 0% and morbidity was 35%. The 5-year overall and recurrence-free survival rates were 43% and 39%, respectively. Multivariate analysis identified the presence of multiple nodules and poor histologic grade as independent negative prognostic factors for overall and recurrent-free survival. Postoperative recurrence occurred in 25 patients (57%). Solitary recurrence occurred in 5 patients (liver, n = 4; lung, n = 1), all of who had undergone surgical resection. Three of the 5 patients survived for more than 5 years after 2 resections. CONCLUSION: Prognosis after curative resection of solitary ICC appears favorable. In selected patients with sequential single hepatic or pulmonary recurrence, repeat resection may prolong survival. CI - Copyright A(c) 2011 Elsevier Inc. All rights reserved. AD - Department of Gastrointestinal Surgery, Cancer Institute Hospital, Koto-ku, Tokyo, Japan. saiura-tky@umin.ac.jp FAU - Saiura, Akio AU - Saiura A FAU - Yamamoto, Junji AU - Yamamoto J FAU - Kokudo, Norihiro AU - Kokudo N FAU - Koga, Rintaro AU - Koga R FAU - Seki, Makoto AU - Seki M FAU - Hiki, Naoki AU - Hiki N FAU - Yamada, Kazuhiko AU - Yamada K FAU - Natori, Takeshi AU - Natori T FAU - Yamaguchi, Toshiharu AU - Yamaguchi T LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20090509 PL - United States TA - Am J Surg JT - American journal of surgery JID - 0370473 RN - Intrahepatic cholangiocarcinoma SB - AIM SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Analysis of Variance MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Bile Duct Neoplasms/mortality/pathology/*surgery MH - *Bile Ducts, Intrahepatic/pathology/surgery MH - Chemotherapy, Adjuvant MH - Cholangiocarcinoma/mortality/pathology/surgery MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - *Hepatectomy/methods MH - Humans MH - Kaplan-Meier Estimate MH - Liver Neoplasms/mortality/pathology/surgery MH - Lung Neoplasms/secondary/*surgery MH - Lymph Node Excision MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*surgery MH - Neoplasm Staging MH - Pneumonectomy MH - Prognosis MH - Reoperation MH - Retrospective Studies MH - Treatment Outcome EDAT- 2009/05/12 09:00 MHDA- 2011/03/01 06:00 CRDT- 2009/05/12 09:00 PHST- 2008/09/09 [received] PHST- 2008/12/20 [revised] PHST- 2008/12/23 [accepted] PHST- 2009/05/09 [aheadofprint] AID - S0002-9610(09)00169-X [pii] AID - 10.1016/j.amjsurg.2008.12.035 [doi] PST - ppublish SO - Am J Surg. 2011 Feb;201(2):203-8. Epub 2009 May 9.